Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells
Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells
复制标题
DOI：
10.1111/j.1749-6632.2012.06629.x
复制
发表时间：
2012-08
影响因子：
5.2
通讯作者：
D. V. van Bekkum;H. Mikkers
中科院分区：
文献类型：
--
作者：
D. V. van Bekkum;H. Mikkers
许多危及生命的血液病现在通过骨髓移植治疗，即，造血干细胞（HSC）的输注。造血干细胞移植是治疗多种代谢性疾病，甚至是实体瘤和一些难治性严重自身免疫性疾病的有效选择。不幸的是，HSC移植的频率和结果受到合适供体短缺的限制。诱导多能干细胞（iPSC）-通过异位表达多能诱导因子获得多能干细胞特征的体细胞-已被提议作为HSC的替代来源。可能的应用包括自体细胞、自体和遗传修饰的细胞或同种异体来源的细胞。在这里，我们提供了一个关于iPSCs独特机遇的视角，并讨论了未来的挑战。
Many life‐threatening hematological diseases are now treated by bone marrow transplantations, i.e., infusion of hematopoietic stem cells (HSCs). HSC transplantations are a valid option for the treatment of a variety of metabolic disorders, and even for solid tumors and some refractory severe autoimmune diseases. Unfortunately, the frequency and outcome of HSC transplantations are limited by a shortage of suitable donors. Induced pluripotent stem cells (iPSCs)—somatic cells that have acquired pluripotent stem cell characteristics by the ectopic expression of pluripotency‐inducing factors—have been proposed as an alternative source of HSCs. Possible applications include cells of autologous, of autologous and genetically modified, or of allogeneic origin. Here, we provide a perspective on the distinct opportunities of iPSCs and discuss the challenges that lie ahead.